GMH HP 75 Injection contains Menotrophin 75 IU, a purified preparation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) derived from the urine of postmenopausal women. It is indicated for the treatment of infertility in both male and female patients. In females, GMH HP 75 Injection is used to stimulate follicular development in anovulatory or oligo-ovulatory women who have not responded to other treatments such as clomiphene citrate. It is also employed in assisted reproductive technologies, including in vitro fertilization (IVF), to promote controlled ovarian hyperstimulation. In males, Menotrophin is utilized to induce spermatogenesis in cases of hypogonadotropic hypogonadism. The dosage and duration of treatment should be individualized based on patient response, monitored through clinical and laboratory parameters including estradiol levels and follicular growth via ultrasound. GMH HP 75 Injection should be administered under the supervision of a healthcare professional experienced in infertility management. Common adverse effects may include ovarian hyperstimulation syndrome (OHSS), injection site reactions, and multiple pregnancies. Caution is advised in patients with ovarian cysts, endocrine disorders, or hypersensitivity to Menotrophin. Proper patient selection and monitoring are essential to optimize therapeutic outcomes and minimize risks.